Abstract: The present disclosure includes systems and methods for beneficiating bauxite residue. The system may comprise a first reaction vessel configured to receive a first stream comprising vanadic acid (H3VO4); and a second stream comprising an alkaline solution. The system may comprise a third stream passed from the first reaction vessel. The third stream may comprise a metavanadate salt. The system may comprise a filter configured to separate a vanadium-rich stream from the third stream. The system may comprise a second reaction vessel configured to receive a fourth stream comprising scandium carbonate (Sc2(CO3)3) and a fifth stream comprising an organic acid.

Abstract: A system for stimulation of a nucleus basalis of Meynert (NBM) of a patient includes an implantable electrical stimulation lead including electrodes and configured for implantation of at least one of the electrodes adjacent to or within the NBM of the patient; and an implantable pulse generator coupleable to the implantable electrical stimulation lead and configured for delivering electrical stimulation to the NBM through at least one of the electrodes of the implantable electrical stimulation lead, the implantable pulse generator including at least one processor configured to, upon user request, during an initial stimulation period, which is at least 1 month in duration and has a start and an end, increase over time at least one of a duration or an amplitude of the electrical stimulation from an initial value at the start of the initial stimulation period to a final value at the end of the initial stimulation period.

Abstract: A system for stimulation of a nucleus basalis of Meynert (NBM) of a patient includes an implantable electrical stimulation lead including electrodes and configured for implantation of at least one of the electrodes adjacent to or within the NBM of the patient; and an implantable pulse generator coupleable to the implantable electrical stimulation lead and configured for delivering electrical stimulation to the NBM through at least one of the electrodes of the implantable electrical stimulation lead, the implantable pulse generator including at least one processor configured to, upon user request, during an initial stimulation period, which is at least 1 month in duration and has a start and an end, increase over time at least one of a duration or an amplitude of the electrical stimulation from an initial value at the start of the initial stimulation period to a final value at the end of the initial stimulation period.

Abstract: What is provided are commemorative pieces of jewelry that include food, beverage, and/or botanical extracts and methods of making the same. An embodiment of a piece of jewelry comprises a mixture including one or more first layers of cured resin and an extract, wherein the mixture is inlaid in the piece of jewelry, and wherein the extract is derived from a food, an alcoholic beverage, a non-alcoholic beverage, a plant or a botanical. The piece of jewelry further comprises one or more second layers of cured resin.

Abstract: A system for stimulation of a nucleus basalis of Meynert (NBM) of a patient includes an implantable electrical stimulation lead including electrodes and configured for implantation of at least one of the electrodes adjacent to or within the NBM of the patient; and an implantable pulse generator coupleable to the implantable electrical stimulation lead and configured for delivering electrical stimulation to the NBM through at least one of the electrodes of the implantable electrical stimulation lead, the implantable pulse generator including at least one processor configured to, upon user request, during an initial stimulation period, which is at least 1 month in duration and has a start and an end, increase over time at least one of a duration or an amplitude of the electrical stimulation from an initial value at the start of the initial stimulation period to a final value at the end of the initial stimulation period.

Abstract: The disclosure relates to implant systems and methods for stimulation of the cochlea, auditory nerve, and/or vestibular system using an intra-cochlear magnetic stimulation electrode array that uses targeted magnetic stimulation to induce neural activation without the need for mechanical transduction. The magnetic field produced by the array stimulates portions of the cochlea or provides signals to the vestibular system.

Abstract: A first aspect of the invention relates to a method of treating a proliferative disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) seliciclib; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said first treatment cycle comprises: (a) administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 to 5 consecutive days for 2 weeks, starting on day d, where d is the first day of treatment with sapacitabine, or the metabolite thereof, in said first treatment cycle; and (b) optionally administering a therapeutically effective amount of seliciclib for 3 to 5 consecutive days for 2 weeks, starting on day (d?1) relative to the administration of sapacitabine or the metabolite thereof, in said first treatment cycle; followed by a rest period of at least 2 weeks, or until treatment-related toxi

Abstract: A first aspect of the invention relates to a method of treating a proliferative disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) seliciclib; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said i first treatment cycle comprises: (a) administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 to 5 consecutive days for 2 weeks, starting on day d, where d is the first day of treatment with sapacitabine, or the metabolite thereof, in said first treatment cycle; and (b) optionally administering a therapeutically effective amount of seliciclib for 3 to 5 consecutive days for 2 weeks, starting on day (d?1) relative to the administration of sapacitabine or the metabolite thereof, in said first treatment cycle; followed by a rest period of at least 2 weeks, or until treatment-related to

Abstract: A mobile scanning system and methods for inspecting contents of a container. Multiple detector plates are arrayed along an arcuate member coupled to a conveyance with wheels, capable of road travel. A source generates high-energy penetrating radiation that irradiates each of the detector plates from a single position. The arcuate member is disposed, during the course of operation of the system, in a vertical plane. The system has one actuator for rotating the arcuate member about a horizontal pivot into a horizontal plane, and a second actuator for further rotating the arcuate member, once rotated into the horizontal plane, about a vertical pivot, so that the arcuate member is contained, for purposes of transport, entirely within a volume defined by a rectangular prism that does not extend horizontally outward from the conveyance beyond any of its wheels.

Abstract: A mobile scanning system and methods for inspecting contents of a container. Multiple detector plates are arrayed along an arcuate member coupled to a conveyance with wheels, capable of road travel. A source generates high-energy penetrating radiation that irradiates each of the detector plates from a single position. The arcuate member is disposed, during the course of operation of the system, in a vertical plane. The system has one actuator for rotating the arcuate member about a horizontal pivot into a horizontal plane, and a second actuator for further rotating the arcuate member, once rotated into the horizontal plane, about a vertical pivot, so that the arcuate member is contained, for purposes of transport, entirely within a volume defined by a rectangular prism that does not extend horizontally outward from the conveyance beyond any of its wheels.

Abstract: A system and method for managing and verifying the installation of software on a modular information handling system includes a bar file database and an installation management module. The bar file database stores bar files. The bar files each are related to a component of a modular information handling system. The installation management module is able to receive a bar file and communicate with the bar file database to identify and access each bar file associated with the modular information handling system.

Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R1 and R5 are each independently H, C(ORj?) or a hydrocarbyl group optionally substituted by one or more R6 groups; R2, R3, and R4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R7 groups; R6 and R7 are each independently halogen, NO2, CN, (CH2)mORa, O(CH2)nORb, (CH2)pNRcRd, CF3, COORe, CONRfRg, CORh, SO3H, SO2Ri, SO2NRjRk, (CH2)qNRa?CORg?, Rf?, (CH2)rNRb?SO2Rh?, SO2NRd?Ri?, SO2NRe?(CH2)sORc?, heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, Rm and CORn; Rg?, Rh?, Ri? and Rj? are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2 CF3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3; n

Abstract: The invention provides a method of targeting a drug to areas of hypoxic and/or ischemic tissue within the body in which the desired drug species is linked to a non-cytotoxic bioreductive carrier. Also provided by the invention are novel bioreductive conjugates comprising a non-cytotoxic bioreductive moiety with linked-thereto at least one therapeutic agent. The compounds of the invention are particularly suitable for the treatment of rheumatoid arthritis and other arthritic conditions, diabetes, atherosclerosis, stroke, sepsis, Alzheimer's disease and other neurological disorders, cancer, kidney disease, digestive diseases, liver disease, chronic periodontitis or ischemia following tissue transplantation.

Abstract: A support device (1) comprises a first support structure (6) which is conformable to an object to be supported, and a second support structure (2) which has an activated state in which the second support structure substantially locks the first support structure into a conformed shape, and supports tensile loading on the support device, and an inactivated state in which the first support structure is able to conform to an object.

Abstract: A system and method for managing and verifying the installation of software on a modular information handling system includes a bar file database and an installation management module. The bar file database stores bar files. The bar files each are related to a component of a modular information handling system. The installation management module is able to receive a bar file and communicate with the bar file database to identify and access each bar file associated with the modular information handling system.

Abstract: A system and method for managing and verifying the installation of software on a modular information handling system includes a bar file database and an installation management module. The bar file database stores bar files. The bar files each are related to a component of a modular information handling system. The installation management module is able to receive a bar file and communicate with the bar file database to identify and access each bar file associated with the modular information handling system.

Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R1 and R5 are each independently H, C(ORj?) or a hydrocarbyl group optionally substituted by one or more R6 groups; R2, R3, and R4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R7 groups; R6 and R7 are each independently halogen, NO2, CN, (CH2)mORa, O(CH2)nORb, (CH2)pNRcRd, CF3, COORe, CONRfRg, CORh, SO3H, SO2Ri, SO2NRjRk, (CH2)qNRa?CORg?, Rf?, (CH2)rNRb?SO2Rh?, SO2NRd?Ri?, SO2NRe?(CH2)sORc?, heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, Rm and CORn; Rg?, Rh?, Ri? and Rj? are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2 CF3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3